An Important Step Forward in ITP: Shreeram Aradhye Shares Ianalumab Phase III Results!
Shreeram Aradhye, President, Development and Chief Medical Officer at Novartis, shared on LinkedIn:
”Today, at the Late-Breaking Abstract Session at the 67th American Society of Hematology Annual Meeting and Exposition, we shared positive results from a Phase III trial in adults with primary immune thrombocytopenia (ITP) previously treated with corticosteroids.
With a course of four once-monthly doses, our investigational therapy studied in this trial offers a promising alternative to chronic treatment.
ITP is a rare autoimmune condition where the immune system mistakenly destroys platelets, leading to prolonged bleeding, easy bruising and chronic fatigue.
This potential treatment is designed to target B cells, a key driver in ITP and other autoimmune diseases, through a dual mechanism of action.
Today’s results represent an important step forward in ITP and add to the growing body of evidence for this therapy, which is currently being studied across multiple B cell-driven conditions.
Thank you to all the patients, investigators, and teams involved in this research.”
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show